Oxford BioMedica (LON:OXB) Share Price Crosses Below Two Hundred Day Moving Average of $0.00

Oxford BioMedica plc (LON:OXB)’s stock price passed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $0.00 and traded as low as $679.00. Oxford BioMedica shares last traded at $690.00, with a volume of 18,687 shares traded.

Separately, Peel Hunt reissued a “buy” rating and issued a GBX 60 ($0.78) price target on shares of Renewi in a research note on Wednesday, July 3rd.

The business has a 50 day moving average price of GBX 722.60. The company has a quick ratio of 2.26, a current ratio of 2.44 and a debt-to-equity ratio of 118.46. The firm has a market capitalization of $529.70 million and a PE ratio of 63.30.

In other Oxford BioMedica news, insider Andrew Heath purchased 3,312 shares of the firm’s stock in a transaction on Tuesday, April 23rd. The shares were purchased at an average cost of GBX 673 ($8.79) per share, with a total value of £22,289.76 ($29,125.52). Also, insider Lorenzo Tallarigo purchased 370 shares of the firm’s stock in a transaction on Wednesday, June 26th. The stock was acquired at an average cost of GBX 722 ($9.43) per share, for a total transaction of £2,671.40 ($3,490.66). Over the last three months, insiders acquired 4,449 shares of company stock worth $3,031,022.

About Oxford BioMedica (LON:OXB)

Oxford BioMedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of lentiviral vector and cell therapy products for the treatment of various cancers, Parkinson's, central nervous system disorders, and ocular conditions in Europe and internationally. The company operates through Platform and Product segments.

Read More: Book Value Per Share – BVPS

Receive News & Ratings for Oxford BioMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica and related companies with MarketBeat.com's FREE daily email newsletter.